AB062. P-33. Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: a pooled analysis from three phase 1 studies

BACKGROUND: Varlitinib is a nanomolar inhibitor of EGFR, HER2, and HER4 and has shown potent anti-tumor activity as monotherapy in preclinical BTC models. During phase (Ph) 1 development, significant tumor shrinkage was observed in biliary tract cancer (BTC) patients (pts). Tissue microarray analysi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepatobiliary Surg Nutr
Main Authors: Tan, Aaron C., Oh, Do-Youn, Chao, Yee, Hsieh, Chih-Yi, Chang, Wei-Ling, Isanto, Fenny, Chen, Ying-Chen, McHale, Mark, Lindmark, Bertil, Ng, Matthew C. H.
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Poster Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6421168/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/hbsn.2019.AB062
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados